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Abstract 
We propose that a fruitful way to understand the extension of molecular biology into 
clinical practice is through the notion of biomedical platform. In this article, we analyze 
the development of the new genetics in clinical haematology since the mid-1980s 
focusing on two recent instantiations of the molecular biology platform: RT-PCR and 
DNA microarrays. We show how clinical research is more closely entwined with 
‘fundamental’ biology than is often imagined and simultaneously caution that the use of 
techniques in clinical research does not automatically entail their use in routine clinical 
practice. The article calls attention to the work of articulation and regulation as 
constitutive aspects of a platform that enters standard clinical use. 
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Signs, Markers, Profiles, and Signatures: Clinical Haematology Meets 
the New Genetics (1980-2000) 
 
The phrase “Someday simple molecular tools will provide an 
objective and quantitative diagnosis for Pap smears and/or other 
cytologic specimens” is getting old. ... NOTE ADDED IN 
PROOF: It has now occurred that a molecular method correctly 
classified tumors without morphological information. (Rimm, 
2000, pp. 1 and 9) 
Introduction 
This article analyzes the operational dynamics of new genetic technologies at the 
interface between laboratory and clinical work. In a very general sense, it focuses on the 
relations between technology and medicine. There are, however, many different ways of 
pursuing such a broadly defined analytical agenda. Consider, for example, Wailoo’s 
(1997) discussion of how medical technologies modified disease definitions in 20th 
century and, in particular, of how the technologies implicated in the development of 
haematology participated in the construction and the transformation of the various 
diseases (e.g. sickle cell anaemia, leukaemia, and so on) constitutive of the specialty, the 
patients targeted by diagnosis and therapy, and, finally, the practitioners themselves. 
Wailoo intends to show that these technologies acquired as much of their meaning and 
power from the cultural context of their use as from their use per se, or, in other words, 
that the technologies were shaped by social, political and cultural forces.  
 
Our approach is less encompassing: we are not so much interested in technology as a 
bridge between society, culture and medicine, as in the material culture of medicine itself. 
Moreover, in contrast to long-range historical surveys (e.g. Reiser, 1978), we seek to 
investigate how, in recent decades, specific kinds of technologies have participated in the 
articulation of biological and clinical practices and thus in the establishment of the novel 
material, epistemic and institutional configurations that, taken together, characterize the 
post-WWII domain of practice known as biomedicine. 
 
Let us briefly consider the context created by biomedicine. Whereas in the early 20th 
century several areas of medical diagnostics became routinely based on technologies 
derived from chemistry and physics (Howell, 1995), in the second half of the century, and 
despite the contributions of nuclear medicine and biophysics (Blume, 1992; Lenoir & 
Hays, 2000), biomedical technologies have become relatively independent of physics and  
chemistry. Indeed, the post-war alliance of biology and medicine has made possible a 
new kind of medical technology that is truly biomedical (Thomas, 1972): generated 
within biology and medicine, these biotechnologies use fragments of living systems such 
as cells, enzymes, antibodies and gene segments (Rheinberger, 2000; de Chadarevian & 
Kamminga, 1998). One of the consequences, but also one of the causes of the use of 
biological tools and variables in the diagnosis of diseases, and thus of the renewed 
alignment of the biological and the medical, has been that the technologies for the 
investigation of the normal and the pathological have become increasingly the same 
(Keating & Cambrosio, 2003).  
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Historical studies have shown, for example, that an experimental system instituted for the 
study of cancer can easily become a system for the study of protein synthesis 
(Rheinberger, 1997). As medical problems thus find their solution through biological 
innovation, the general perception is that the transfer of concepts and techniques from 
fundamental biology to medical practice has been vastly accelerated, a perception 
embodied in the notion of translational research (e.g. Chabner, Boral & Multani 1998). 
Conversely, observers have also noted that medical problems have prompted many 
fundamental biological investigations (Sinding, 1991). Finally, clinical trials, the 
hallmark of so-called evidence-based medicine, are no longer restricted to the testing of 
therapies. Since the 1960s, an expanded notion of clinical trial now includes the study of 
biological (genetic) markers and etiological research. No longer solely a determination of 
the efficiency of treatment, clinical trials are simultaneously an exploration of human 
biology (Löwy, 1996; Keating & Cambrosio, 2002; forthcoming). 
  
In order to capture the new dynamics of biomedical innovation, sociologists of science 
have advanced a number of analytical categories. Consider, first, Fujimura’s (1992; 1996) 
notion of standardized packages, which she defines as ‘theory-methods packages’ whose 
description shows “how tools, practices, and theories circulate through and across worlds 
of practice … and both change and are changed by their circulation”. In practice, 
Fujimura’s application of her concept results in the recapitulation of the actors’ 
narratives, insofar as it tells the story of how biomedical innovations (in her case, 
oncogene theory and related techniques) emerged from within a few elite biology 
laboratories and spread, as a pre-packaged technique, to lower-level clinical laboratories 
(for a similar criticism, see Gaudillière, 1993; Morange, 1997). In other words, 
Fujimura’s “theory-methods package”, because it adheres so closely to the actors’ 
accounts, becomes little more than a description of a linear process of innovation leading 
from the laboratory to the clinic. Such a narrative omits all mention of clinical work in 
the innovation process itself. In this sense, standardized packages do not so much 
circulate as drive the teleological accounts offered by participants. 
 
Rheinberger’s (1997) notion of ‘experimental system’ avoids this pitfall insofar as it 
takes into account the previously mentioned fact that, for instance, an experimental 
system instituted for the study of cancer can easily become a system for the study of 
protein synthesis. In this sense, it crosses the biology-medicine divide. Experimental 
systems also cross the science/technology divide, insofar as the difference between 
science (epistemic things) and technology is generated within an experimental system. 
While experimental systems enter into the description of biomedical research, they do 
not, however, cover the whole range of biomedical practices that stretch from the clinic to 
research. In particular, they do not account for the regulation of the epistemic things they 
generate once they have been translated into routine practices.  
 
In order to overcome these problems, we recently introduced the notion of biomedical 
platforms as a means to describe the constitution of medical innovations and routines in 
the post-WWII era (Keating & Cambrosio, 2000; 2003). 
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Biomedical Platforms  
Briefly put, we claim that, since WWII, biology and medicine have come together, both 
institutionally and intellectually, in a hybrid practice that is neither syncretic nor 
synthetic. We argue, in other words, that a new way of conducting research in biology 
and medicine has emerged. The new, in this instance, is characterized by a pathology that 
is aligned but not fused with the normal and a problematic space of scientific 
representation (Rheinberger, 1997, pp. 102-13) that is the result of this realignment. 
Within this space, truly biomedical entities—e.g., cell surface markers, oncogenes, DNA 
microarray signatures, etc.—exist as both normal biological entities and as pathological 
signs, i.e., as biomedical substances with regards to their origins, their uses and their 
meanings. In this context, we define biomedical platforms as material and discursive 
arrangements that act as the bench upon which conventions concerning the biological or 
normal are connected with conventions concerning the medical or pathological. We use 
this category to describe a range of activities in contemporary biomedicine running from 
laboratory research to clinical trials and routine diagnosis. 
 
As an example of what we mean by biomedical platforms, consider Figure 1, a 
representation of a hierarchical set of procedures used to diagnose lymphoid tumours first 
published in 1991. Confronted with a patient presenting telltale clinical signs, a clinician 
will request a biopsy. The resulting tissue sample will first be examined by a trained 
pathologist who, with the help of a microscope and histochemical dyes, will investigate 
the architectural arrangement and the shape and size of the cells in the sample (Foster, 
1961). This morphological analysis can lead directly to a final diagnosis. But 
morphological analysis is often—and in difficult cases routinely— supplemented by 
immunophenotypic analysis. For this investigation, panels of standardized antibodies are 
combined with the use of computerized, laser-based equipment to detect the presence or 
absence of distinctive cell surface molecules indicative of the diagnostic sub-group of the 
disease. An additional more recent diagnostic step—that will be the focus of this article—
is provided by molecular genetics. Suspicious cells are examined for culpable DNA 
fragments and genes using techniques such as, in their chronological order of appearance, 
Southern Blot, RT-PCR and DNA microarrays. Figure 2 depicts the same process as 
Figure 1 about 10 years later, with additional specifications concerning molecular 
genetics.  
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FIGURE 1 
 
 
A hierarchical representation of sequential steps in the diagnosis of lymphoid 
tumours in 1991. Reprinted from Whittaker & Willman (1991, p.124), © 1991, 
with permission from the United States and Canadian Academy of Pathology. 
FIGURE 2 
 
Sequential steps in the diagnosis of lymphoid tumours in 2000, with a focus on 
molecular genetic techniques. Reprinted from Arber  (2000, p. 186), © 2000, with 
permission from the Association for Molecular Pathology and the American 
Society for Investigative Pathology. 
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The three scenarios are each characterized by a distinctive configuration of techniques, 
instruments, reagents, diagnostic and laboratory skills, organic entities (cell 
morphologies, cell markers, genes), spaces of representations, diagnostic, prognostic and 
therapeutic indications and related etiological accounts. Each of these configurations 
constitutes a separate biomedical platform, so that it is possible to speak of a 
morphological platform, an immunophenotypic platform and a molecular genetic 
platform. Although platforms emerge in chronological order, the development of a new 
platform does not result in the replacement of the previous ones. Rather, new platforms 
are articulated and aligned in complex ways with the pre-existing ones, and thus 
integrated into an expanding set of clinical-biological strategies. 
 
Platforms cannot be reduced to mere technology  or infrastructure (Star & Ruhleder, 
1996), insofar as they generate and reproduce specific etiological accounts and 
biomedical entities. Consider, for instance, the immunophenotyping (IPT) platform. The 
term IPT, as previously mentioned, refers to the investigation of distinctive markers or 
antigens on the surface of cells using antibodies that selectively bind to these substances, 
fluorescent dyes conjugated to the antibodies to visualize the bound antibodies, and 
sophisticated equipment to do the visualizing and counting, in the simplest case a 
fluorescence microscope, but in most cases a computerized apparatus able to count 
thousands of fluorescent cells per second.  IPT, however, began in the field of leukaemia 
as a search for unique cell surface markers that were, in other words, distinctive 
diagnostic signs for cancer cells. Soon, however, IPT was translated into a new 
etiological account of leukaemia, according to which cancer cells are not mature cells that 
have undergone some process of degeneration (a stance attributed to morphological 
pathology), but are, in fact, normal cells whose development has been arrested at a stage 
prior to final maturation. The markers detected by IPT are thus ‘normal’ markers of cells 
frozen at a given developmental stage. One would thus no longer speak of leukaemia-
specific markers but, rather, of leukaemia-associated markers. In other words, IPT 
aligned biological and pathological variables so that it became possible to speak, in a 
strong sense, of a biology of leukaemia. Figure 3 is a visual representation of this 
etiological account: each cell differentiation stage (pre-B-cell, early-B-cell, etc.) is 
characterized by a list of markers expressed at that stage; the black ribbon running above 
the cells features the names of the specific kinds of leukaemia (pre-B-ALL, B-ALL 
where ALL means Acute Lymphoblastic Leukaemia, etc.) that correspond to a maturation 
arrest at a given stage. A single differentiation path thus accounts for both normal and 
pathological developments.  
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FIGURE 3 
 
Immunophenotypic representation of normal and pathological lymphoid 
differentiation. See text for explanations. Reprinted from Van Dongen & 
Adriaansen.  (1996, p. 91), © 1996, with permission from Elsevier Science. 
Given that the alignment of the normal and the pathological is a central feature of 
biomedical platforms, it is not surprising to find striking parallels between the accounts 
generated by the IPT platform and by the succeeding molecular genetic platform. 
Consider, for example, a recent article published in the Health & Science section of a 
daily newspaper describing advances in the molecular genetic analysis of tumours 
(Pollack, 2002). Readers are told that while tumours were traditionally classified 
primarily according to their anatomical site of origin (e.g., lung, colon, breast, blood 
cancers), genetic analysis shows that tumours developing in different anatomical 
locations may share the same genetic characteristics (or ‘signature’) and thus be, in fact, 
the same disease. The underlying story here is that an old method or platform 
(pathological anatomy) is about to be replaced by a new platform (molecular genetic 
analysis). Similar claims emerged when the IPT platform was initially developed: then, 
researchers suggested that morphologically distinct (sub)types of cancer might in fact 
belong to the same category as that defined by the use of immunological techniques 
targeting cell surface markers. Both of these revolutionary claims (insofar as they 
threatened to relegate time-honoured pathological classifications and techniques to the 
dustbin of medical history) confronted, however, powerful counterclaims according to 
which the clinical considerations entrenched in morphological and anatomical 
distinctions remained critical components of the biomedical enterprise. In concrete terms: 
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the pathologists quoted in the 2002 newspaper article pointed out that even if tumours 
belonged to the same genetic category, they could very easily grow differently in a 
different anatomical environment, and would thus have different clinical courses. Indeed, 
as shown by Figures 1 and 2, the new platforms were hierarchically subordinated to the 
previous ones, according to an “algorithm” that gave diagnostic precedence to 
morphology over IPT and molecular genetics, in a context where these platforms could 
not always be aligned. 
 
These remarks suggest that the alignment of the clinical and the biological is an open-
ended problem and that, rather than a distinctly defined domain, biomedicine is an 
ongoing project. In this paper we would like to explore this project further by examining 
one of the latest biomedical platforms to emerge, molecular genetics. Two general 
restrictions apply to our present paper. First, we have chosen to concentrate on the 
constitution of the molecular genetics platform in relation to the immune and blood cell 
cancers that lay at the centre of the development of the IPT platform. Secondly, we have 
already discussed elsewhere the contributions of clinical medicine to the development of 
the “new genetics” in the 1970s and early 1980s. We have shown, in particular, that 
rather than a direct technology transfer from biology to medicine, recent developments 
are more appropriately described in terms of an interaction within the framework of a 
larger activity termed biomedicine (Keating & Cambrosio, 2001). These restrictions thus 
limit our analysis to the development of the new genetics and the new molecular biology 
techniques within the field of clinical haematology since the mid-1980s and the two most 
prominent instantiations of the molecular biology platform: RT-PCR and DNA 
microarrays. 
Restriction Enzymes, Southern Blot, and Northern Blot (1979-1988) 
The first genetic engineering techniques used for clinical purposes, namely those 
involving restriction enzymes, coincided with the laboratory production of the first 
human restriction fragment length polymorphisms (RFLPs), a technique used to screen 
human DNA for the presence of potentially deleterious genes.1 First encountered by Kan 
& Dozy (1978) as part of a clinical research project on sickle cell anaemia, the original 
human RFLPs were thus not a product of biological investigations. The RFLPs were put 
to clinical use shortly thereafter when the DNA fragments obtained through the use of 
restriction enzymes were identified using a number of hybridization techniques, the 
earliest and most widespread of which was the Southern Blot developed in 1975 
(Southern, 2000).2 Similar techniques for the hybridization of RNA fragments such as the 
Northern blot were soon produced. 
                                                          
1 Restriction enzymes cut DNA at specific points producing a collection of DNA fragments of defined 
length that can be separated by electrophoresis. Polymorphisms are inherited differences found among the 
individuals in a population. Difference in DNA sequence between individuals affects the recognition 
sequence for restriction enzymes and when DNA is digested by a particular enzyme the fragment sizes will 
differ depending on the presence or absence of the proper recognition sequence for the enzyme. For any 
given gene it is often possible to test different restriction enzymes until one is found which gives a pattern 
difference (a RFLP) between two individuals. 
2 In a Southern Blot, after the various DNA fragments have been separated by gel electrophoresis, the DNA 
is rendered single-stranded, attached to a sheet of nitrocellulose paper, and hybridized with radioactive 
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Sickle cell specialists were not, of course, alone in the detection of faulty genes for 
diagnostic purposes. Within the field of the leukaemias and the lymphomas, significant 
work accumulated in the late 1970s and early 1980s relating genetic events such as gene 
rearrangements3 to specific diseases. Carried out within the framework set up by the IPT 
platform, this work set out to refine categories based on cell surface markers at the DNA 
level. Two brief examples of the kind of work involved will suffice to show the degree to 
which the molecular work was indeed dependent upon and articulated with previous 
histopathology and IPT.  
 
First, consider a study carried out by Philip Leder and his colleagues at the NIH in the 
early 1980s. Working with a specific kind of leukaemia, and using restriction enzymes 
and related molecular hybridization techniques, they identified a series of gene 
rearrangements affecting a type of protein known as immunoglobulins that are 
characteristically produced by B cells. Aligning the normal with the pathological, they 
hypothesized that in the normal process of B-cell differentiation, the genes would be 
activated in a specific order. Genes that failed to activate would fail to make protein thus 
creating the conditions where standard IPT methods involving the detection of 
immunoglobulins would fail. They found, surprisingly they say, that most of the cases 
that had been classified on the basis of the absence of protein markers, did, in fact, have 
genes for immunoglobulins. This meant that the cells in question were B cell precursors 
but that gene rearrangement had presumably rendered them inapt to produce 
immunoglobulin (Korsmeyer et al.,1981). Leder and his associates then went on to 
propose a sub-classification of the (pathological) leukaemic immunoglobulin gene 
disorders according to the normal order of gene activation as shown in Figure 4. In spite 
of the fact that the molecular genetic approach pointed to the presence of events missed 
by IPT analysis, there is a striking resemblance between the molecular genetic diagram 
and the IPT diagram shown in Figure 3: both diagrams articulate the normal with the 
pathological within the same space of representation. As mentioned at the end of the 
previous section, the fact that this common scheme runs through different platforms is 
what makes them distinctively biomedical.  
 
                                                                                                                                                                             
genetic probes (DNA sequences of known composition) that will show up on a film, thus allowing 
researchers to identify the occurrence and  frequency of particular genetic patterns. 
3 The term gene rearrangement refers to the process involving the breakage and re-sealing of chromosomes 
and thus the movement of a gene or group of genes to a different location within the same chromosome or 
to a different chromosome. 
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FIGURE 4 
 
Hypothetical differentiation scheme showing gene rearrangements in pre-B-cell 
leukaemia. The illustration aligns normal and pathological entities and events. 
Reprinted from Korsmeyer et al. (1981, p. 7099). with permission from the 
authors. 
Our second example concerns the lymphomas. Following Leder’s example, Sklar and his 
colleagues at the Stanford University Department of Pathology undertook technically 
similar work with the lymphomas (Cleary et al., 1984). Starting with B-cell lymphomas, 
they confronted the same problem as that encountered in the leukaemias. Specifically, at 
the time, tumours were generally considered of B-cell origin if the immunoglobulin 
surface markers detected through IPT signified B-cells. Alternatively, if no markers were 
present but immunoglobulin could be detected inside the cells, then, once again, 
diagnosticians concluded that the tumour originated in a derangement of the B cells. 
However, as claimed by the authors, some lymphomas that did not display B cell markers 
either at the surface or inside the cells, did show immunoglobulin gene rearrangements 
thus demonstrating a B-cell (or at least pre-B-cell) origin to the tumour. Comparing their 
findings to the information provided by the morphology platform, and shifting to clinical 
considerations, the authors, however, added: 
 
Clonal immunoglobulin gene rearrangements were found in every 
histologic subtype of B-cell lymphoma tested. Analysis of immunoglobulin 
gene arrangements fails to distinguish between these subtypes and, 
therefore, provides no information about expected biologic behavior (e.g. 
clinical aggressiveness), as can be obtained from the morphologic 
characteristics of the tumor. (Cleary et al., 1984, p. 597) 
 
There are several features of these two examples worth noticing. As previously 
mentioned, while of diagnostic value, detection of the genes for the surface marker 
refined without necessarily replacing or displacing the grounds of the morphological and 
IPT classifications already in place: at the very least, the issue of aligning information 
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provided by these different platforms remained a central one.4 Second, and partly for 
similar reasons, neither of these two contributions made much headway in terms of 
routine clinical analysis. A variety of factors, which form part of a larger pattern, 
conspired to confine genetic analysis to the clinical research laboratory. Generally 
speaking, the various forms of molecular genetic analysis such as Southern and Northern 
blotting offered little more clinical information than conventional immunohistochemistry 
(Whittaker & Willman, 1991). When they did, it was as ancillary techniques. As the 
course notes to the 1990 Special Course in Diagnostic Molecular Pathology initiated by 
the United States and Canada Academy of Pathology a year earlier tell us: “Molecular 
genetic techniques are usually employed [for lymphoid malignancies] when clinical, 
morphological and immunophenotypic studies are inconclusive” (Whittaker & Willman, 
1991, p. 124). The ancillary nature of molecular genetics techniques is emphasized in one 
of the course overheads that we have already seen as Figure 1. A decade later, as we saw 
in Figure 2, the diagnostic algorithm had not changed despite the enormous development 
in PCR methods (see next section) and the resultant conflicts between methods. As in 
1990, so in 2000: “The vast majority of leukemias and lymphomas can be diagnosed 
without the use of molecular genetic or cytogenetic studies” (Arber, 2000, p. 178). In 
sum, while the use of restriction enzymes and hybridization techniques generated 
information hitherto unavailable to pathologists, the diagnostic routines that used them 
remained time-consuming, expensive and slow.  
 
Nonetheless, professional boards have duly recognized the inroads made by molecular 
analysis at the research level. In 1999, the Assembly of the American Board of Medical 
Specialties approved the joint application made by the American Board of Pathology and 
the American Board of Medical Genetics to create a subspecialty entitled Molecular 
Genetic Pathology (Byers, 1999). At the same time, the Association for Molecular 
Pathology, formed in 1994, joined forces with the American Society of Investigative 
Pathology to create a Part B for The American Journal of Pathology entitled The Journal 
of Molecular Diagnostics (Fausto & Kaul, 1999). Let us thus examine the more recent 
instantiations of the molecular genetic platform. 
The PCR Revolution (1985-1995) 
The development of the Polymerase Chain Reaction (PCR) is one of the success stories 
of biotechnology and has duly attracted the attention of social scientists (Rabinow, 1996). 
The technique allows for the amplification of specific sequence of DNA up to one billion 
times: it thus permits the analysis of any short sequence of DNA without having to go 
through the time-consuming process of cloning. In principle, the PCR revolution has 
considerably accelerated the spread of molecular genetics techniques in the clinical 
laboratory. Although often hailed as a classic case of serendipitous, pure research within 
a biotech company, PCR moved into the clinical world so instantaneously that it is 
difficult to speak of application and, consequently, any notion of purity remains entirely 
relative. Even as Kary Mullis, the Cetus researcher who received the Nobel prize for the 
development of the PCR technique, wrote up the paper explaining the basic PCR 
                                                          
4 For pathologists: “In situ hybridisation has failed to make an impact because until now it has offered little 
that conventional immunohistochemistry cannot provide” (McCarthy, 1997). 
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protocol, a second group at Cetus Corporation, lead by Randall Saiki, simultaneously 
worked on the first ‘application’ of the technique developing a diagnostic test for sickle 
cell anaemia. Moreover, the application appeared in print prior to publication of the 
technique.5 Only later, in 1989, did Science hail PCR as its first ‘molecule of the 
year’(Cook-Deegan, 1994, pp. 72-4). 
 
Saiki’s group had not chosen sickle cell anaemia at random as a target PCR application. 
Following the previously mentioned work by Kan & Dozy, which they duly 
acknowledged, routine diagnostic tests had emerged to directly detect sickle cell DNA in 
foetal blood using Southern blotting (e.g. Orkin, Markham & Kazazian, 1983). Sickle cell 
anaemia and other pathologies affecting the haemoglobin molecule, in other words, 
constituted the model system for the routine diagnostic detection of diseased genes in 
humans and the standard against which competing methods could be tested (Feldman & 
Tauber, 1997). We thus understand why the first paper published on PCR claims: “We 
have developed a procedure for the detection of the sickle cell mutation that is very rapid 
and is at least two orders of magnitude more sensitive than standard Southern blotting” 
(Saiki et al., 1984, p. 1350, our emphasis).6  
 
One of the most successful applications of the PCR technique in clinical immunology has 
been in the form of reverse transcriptase PCR (RT-PCR).7 This variant of PCR was 
developed in 1988 and by the end of 2001 over 30,000 articles using the term RT-PCR in 
the title or abstract of the article had been indexed in Medline (see Figure 5). Once again, 
Cetus played a central role and the biological and the clinical forms appeared more or less 
simultaneously.8 In the clinical case, RT-PCR proved to be less an application of biology 
to medicine than a biological solution to a problem raised in the clinic. Specifically, the 
presence of aberrations, namely translocations, affecting cell chromosomes in lymphoid 
tumours had long been observed. For instance, the Philadelphia chromosome,9 present in 
95% of cases of a subspecies of leukaemia known as chronic myelogenous leukaemia 
(CML) (Chopra, Pu & Elefanty,1999), became associated with the disease in 1959 and 
had already been used as a disease marker in a number of clinical studies throughout the 
1960s and 1970s. At the beginning of the 1980s, researchers pointed to the presence, at 
                                                          
5 Saiki’s paper appeared in December of 1984 (Saiki et al., 1984). Still in preparation at the time of the 
Saiki publication, Mullis’ paper was subsequently refused by both Nature and Science and did not appear 
until 1987 (Mullis & Faloona, 1987). 
6 Saiki et al. (1984, p. 1353), also pointed out that compared to the standard prenatal diagnosis of sickle cell 
anaemia, their test required 10 hours rather than several days and that “all of the reactions can be done in 
two small microcentrifuge tubes and could readily be automated”. 
7 RT-PCR uses messenger RNA (mRNA) instead of DNA as its starting point. When genes are active, their 
DNA is transcribed into mRNA and subsequently into proteins. In RT-PCR, using an enzyme called 
reverse transcriptase, the mRNA is translated back into DNA (more precisely: complementary DNA or 
cDNA) and the latter is then amplified using PCR. 
8 The simultaneous nature of the invention is attested to by the authors of the clinical paper who noted in 
their final sentence: “while this manuscript was in preparation, two studies were reported in which 
amplification of RNA sequences was used (i) to determine the mechanism for tissue-specific processing of 
an apolipoprotein and (ii) to facilitate cloning of the HLA-DQ sequences” (Kawasaki et al., 1988, p. 5702). 
9 A translocation is one type of gene rearrangement (see note 3). In the case of the Philadelphia 
chromosome, the latter is formed when a portion of chromosome 22 is translocated to chromosome 9. For a 
recollection of events related to the Philadelphia chromosome, see Rowley (2001). 
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the translocation breakpoint, of a human homologue of a murine leukaemia virus (de 
Klein et al., 1982), and CML became a model disease providing a molecular or genetic 
reading of the translocation event.  
FIGURE 5 
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Growth of the number of papers indexed in PubMed with the term RT-PCR. 
When researchers at Cetus began work, there were several ways of spotting the molecular 
trouble at the base of the disease. The translocation had initially been characterized  using 
the Southern blot and restriction enzymes (Kurzrock, Gutterman & Talpaz, 1988). The 
DNA sequence associated with the translocation was thus an obvious target for PCR 
amplification. Due, however, to the presence of large non-coding sequences of DNA 
within the gene, inter-patient variation and, above all, the fact that breaks occurred 
anywhere within a large region of the chromosome, standard PCR protocols could not be 
used. In collaboration with clinical researchers at the Department of Pediatrics at the 
Stanford Children’s Hospital and the Department of Hematology at the University of 
California Center for the Health Sciences, Cetus researchers set out to overcome these 
impediments. Using reverse transcriptase they were able to isolate much shorter and 
homogenous fragments of DNA and subsequently apply PCR techniques (Kawasaki et 
al., 1988). Shortly thereafter, researchers associated with a U.S. Cooperative Oncology 
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clinical trial group used the RT-PCR technique to detect presence of residual cancer cells 
in CML patients that had undergone therapy (Lee et al., 1989). By the mid-1990s, the 
analysis of translocation breakpoints entered the era of optimization and quantification 
(Cross et al., 1994; Malcomson et al., 1995) and techniques developed in one domain 
were quickly transferred to the analysis of other domains (Lynas et al., 1995).10 
 
So, to sum up, while the PCR episode is often presented as an instance of the veni, vidi, 
vici dynamics whereby biology techniques have swept the clinical domain, a closer look 
reveals the existence of mutual regulatory relations between the clinical and genetic 
research, similar to those already found in the case of the early molecular genetic 
techniques such as Southern Blot.  
Gene Expression Profiling: From Markers to Signatures (1995-2000) 
The light at the end of the reductionist tunnel has turned out to be 
the headlight of a locomotive called genomics. (Shaffer et al., 
2001, p. 375) 
 
The latest articulation of the molecular biology platform to enter the clinical haematology 
arena is the DNA microarray or DNA chip. A microarray consists of a small solid surface 
(generally glass) on which individual DNA samples (up to thousands of them) are 
arranged in a grid.11 In a typical run, a technician will investigate the differential 
expression of genes using, say, a breast cancer specimen and a normal tissue specimen by 
hybridizing them with the DNA sequences present on the microarray.12 To quote one of 
the developers of the technique, “the fluorescent signal at the spot in the array 
representing each individual gene provides a quantitative readout of the level of 
expression of that gene in the sample. This simple procedure offers a systematic way to 
                                                          
10 The journal issue in  which the Lynas et al. (1995) appeared was the first issue of a subedition of the 
Journal of Clinical Pathology. The reasons for the creation of the new Journal—to familiarize clinicians 
with results and techniques that do not have immediate application but that may in future prove useful—are 
explained in Anon. (1995). 
11 There are, in fact, two main variants or formats of microarrays. In the first case, DNA spots are deposited 
by a robot onto a coated glass slide; this approach allows for the use of two different fluorescent colours 
(and thus the simultaneous analysis of, say, a control and a diseased tissue sample) on the same microarray. 
In the second kind, developed and sold by Affymetrix under the trademark GeneChip, photolithographic 
methods are used to synthesize hundreds of thousand of oligonucleotides on a small glass surface. For a 
description and comparison of these two formats, see, e.g., Gerhold, Rushmore & Caskey (1999). For an 
illustrated description of microarray equipment see Cheung et al. (1999). For simplicity’s sake, and because 
most of the early important contributions in the clinical field have used the “spot” microarray format, our 
discussion will focus on this latter format.      
12 The term gene expression refers to the process by which the information coded in a gene is converted 
into the structures present and operating in the cell, i.e., proteins or RNAs. The genetic material extracted 
from the two specimens is labelled with different fluorescent dyes (e.g. green and red) and incubated with 
the microarray. Gene active or expressed  in the sample tissues will hybridize with their counterpart fixed to 
the microarray and the result of this hybridization process will become visible as a fluorescent spot at a 
specific grid location, therefore showing what genes are busy in what disease (Steinberg, 2000; Southern, 
2001). 
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monitor expression of tens of thousands of genes simultaneously, in thousands of samples 
per year”.13  
 
The growth of the technique, as measured through publications has been quite substantial 
(see Figure 6). Other indicators, such as an estimated annual compounded market growth 
rate of 63% between 1999 and 2004, similarly support the claim that “the genomics 
research community has embraced … microarrays” (Constans, 2003). Unsurprisingly, 
microarray technology and gene expression profiling have elicited quite a reaction. We 
will see some in what follows but let us begin with a historian’s reaction.  
 
FIGURE 6 
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Growth of the number of papers indexed in PubMed with the terms 
“microarray” or “DNA chip.” 
 
Some commentators have suggested that the emergence of DNA microarrays represents 
more than a simple quantitative movement from the analysis of single genes transcripts 
(RT-PCR) to many gene transcripts (microarrays). It is a question of quality insofar as 
microarrays represent the transition from the singular to the global. It is also epochal in 
the sense that it is suggested that RT-PCR represents the failure of the oncogene 
paradigm whereas microarrays express a newer and more profound understanding of the 
                                                          
13 Howard Hughes Medical Institute Website; Description of Patrick Brown’s research concerning 
microarrays: http://www.hhmi.org/research/investigators/brown.html. 
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cancer process. Describing the fading hopes of a complete description of the cancer 
process through a description of oncogenes, Morange (2000, p. 1152) tells us: 
 
In 1982, when the first genes were discovered that, when mutated, led to 
cell transformation and tumorigenesis (the ‘oncogenes’), it might have 
seemed reasonable to expect to isolate and characterize a small group of 
genes responsible for all forms of cancer. In 1986, when the human 
genome sequencing project was first proposed, one of its justifications was 
the hope of isolating not the genes involved in the first steps of 
oncogenesis, which are relatively well known, but the genes responsible for 
the later steps of tumor evolution such as metastasis. 
This hope is now considered to be an illusion. The existence of oncogenes, 
which when mutated are involved in cancer, has been amply confirmed. 
The illusion is that oncogenes constitute a distinct group of genes which 
can be easily described. Hopes are now turned toward a global description 
of transformed cells and their characteristic patterns of gene expression, in 
comparison with the normal untransformed cell.14 
 
Is it truly the case that we have moved from the local to the global? While conceding that, 
technically speaking, a microarray test, when compared to previous molecular genetic 
approaches, involves the simultaneous analysis of many hundreds or thousands of genes, 
as opposed to single ones, could we not maintain that, in both cases, the analysis operates 
at a similar level of representation? What does it mean, for instance, to claim, as 
researcher do in the case of cancer diagnosis, that we have moved from individual 
markers not so much to the global, but, more specifically, to patterns, profiles or 
signatures? We will return to this question but  first, following once again our analytical 
strategy, we need to relate the development of microarrays to their clinical use. 
 
A review of microarray technology that appeared in the journal Nature offers a rational 
reconstruction of the origins of the innovation suggesting that the technology emerged 
from a biological demand. According to Liotta & Petricoin (2000, p. 48), the intrinsic 
complexity of biologic systems and the recent completion of the human genome have 
prompted biomedical researchers to demand “more sophisticated platforms for studying 
the activity of many genes or proteins in parallel”. Hence, DNA microarrays. Be that as it 
may, on a more empirical level, DNA microarrays as presently used in clinical 
immunology emerged out of collaboration between the NCI and Stanford University. 
Alerted by the fact that two papers published by the Stanford-NCI group in the same 
issue of Nature Genetics (Ross et al., 2000; Scherf et al., 2000) had attained the status of 
‘hot papers’, The Scientist sent a reporter to inquire into the origins of the collaboration 
(Kling, 2002b).  
 
According to The Scientist, it seems that in the late 1990s, John Weinstein, a senior 
investigator at NCI’s Division of Basic Sciences (Laboratory of Molecular 
                                                          
14 Morange (2000, p. 1152) adds: “It could be objected that the failure of this project was foreseeable. 
Oncogenes are not a natural, physiological category. Cancer is not a physiological process, but a de-
regulation of normal processes, and the category of oncogenes exists only in the minds of biologists and 
physicians. But developmental biologists have the same difficulty in categorizing genes”. 
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Pharmacology) presented his work on the NCI cancer-drug screening program at Stanford 
University. Patrick Brown, one of the pioneers of microarray technology and a Howard 
Hughes Medical Institute investigator at Stanford attended the talk. Until then, we are 
told, Brown had worked on gene expression in yeast cell lines and Weinstein had been 
following one gene at a time in an attempt to reconstruct oncogene pathways (Brown & 
Botstein, 1999). The two decided to combine their efforts and the results, a profile of 
about 8,000 genes followed through 60 cancer cell lines, appeared in the aforementioned 
Nature Genetics articles. 
 
While the article in The Scientist stresses the serendipitous nature of the encounter, 
placed in its historical context, the collaboration seems less the unlikely fusion of 
Brown’s ‘basic cell biology’ and Weinstein’s ‘pharmacology-driven work’ than 
biomedicine as usual.15 To begin with, the reporter (and his informants) overlooked the 
fact that this was not the first collaboration between Brown’s laboratory and cancer 
researchers. Four years prior to the Brown/Weinstein collaboration and immediately after 
the development of microarray technology, Brown’s laboratory entered into collaboration 
with members of the Laboratory of Cancer Genetics at the NIH to develop a biomedical 
microarray. The chip that they assembled contained a mix of both normal and 
pathological DNA sequences (DeRisi et al., 1996). Brown’s laboratory contributed the 
normal DNA while the NIH lab contributed DNA selected from a human melanoma cell 
line that had originally been produced at the University of Michigan Medical School (Ray 
et al., 1996). The paper published with the Brown team received a more than respectable 
534 cites in the five years following its publication There was thus no five-year delay 
between the invention of microarrays and their clinical application. Biological and 
biomedical microarrays were constructed at the same time. 
 
In addition to this historical oversight, closer examination of the clinical research 
program at the National Cancer Institute shows to what extent it was an innovative and 
parallel enterprise and, thus, much more than fallow ground waiting for biological 
application. To see how this is so, we need to focus less on the novelty of the microarrays 
than on the organization of cancer research. In particular, we need to notice that “high 
throughput” biomedicine has a longstanding tradition at the NCI and created an 
environment where the Brown/Weinstein collaboration would seem only natural. 
High Throughput Biomedicine 
Let us begin with the aforementioned screening system set up at the National Cancer 
Institute to screen for anti-cancer compounds. High-throughput biomedicine begins well 
before the advent of molecular genetics. Screening techniques, first confined to animal 
systems, have subsequently been progressively developed with cell and gene systems. 
The process, of a quasi-industrial nature, was instituted in the mid-1950s, and by 1965 the 
NCI had screened over 100,000 compounds for anti-cancer activity (Goodman &  Walsh, 
2001, Chapter 1). The animal tumour systems used for this purpose were varied and 
complex ranging from more than a dozen different animal tumours in the initial 1955 
                                                          
15 Indeed, Weinstein pursued a similar collaboration with the leading commercial producer of microarrays, 
Affymetrix, as part of a collaboration with Eric Lander of the Whitehead Center for Genomic Research. 
The first results of this research appeared in Staunton et al. (2001). 
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primary screen to a mouse leukaemia mouse model and a solid rat tumour by the mid-
1960s. These two tumour models remained standard until 1975 when, as the number of 
compounds going into the system was scaled back from 40,000 per year to 10,000 per 
year, eight new mouse and human tumours were added. Evaluation of the system seven 
years later, however, showed that the need for more models had been somewhat 
overestimated as most compounds selected for further testing would have been picked up 
by only three models (Anon., 1982).  
 
By the early 1980s, a number of human cancer cell lines had emerged in laboratories 
around the world (Finlay & Baguley, 1984). Thus, by the mid-1980s, in vitro testing 
emerged as an option to be used  in parallel to the in vivo screen. Human cell lines were 
collected at the NCI and work on the construction of a comprehensive panel to screen 
anti-cancer agents. By 1985, cell line panels included melanoma, renal cell carcinoma, 
ovarian carcinoma, CNS tumours, prostate carcinoma, human leukaemia, breast 
carcinoma and lung cancer. An initial test using 100 compounds chosen at random 
showed the panel to be sufficiently sensitive to merit further refinement (NCI Division of 
Cancer Treatment, 1985-1986, p. 8). Panel developers initially intended to use between 
60 and 100 different cell lines (NCI Division of Cancer Treatment, 1987-1988, p. 9; 
Shoemaker et al., 1988; Monks et al., 1991). Statistical methods—including a computer 
program called COMPARE—developed by Kenneth Paull and Robert Shoemaker of the 
biostatistical centre pared the panel down to 60 cell lines (Zaharevitz et al., 2002; Paull et 
al., 1989). Although subsequently criticized on both sides of the Atlantic as a poor 
predictor, the screening system has now been in use for over a decade (Robert, 1996; 
Brown, 1997). 
 
The database generated by the screen had been mined prior to the Weinsten/Brown 
encounter. Paull’s groups, for example, had searched through response profiles generated 
by the panel to search for multidrug-resistant phenotypes (Wu et al., 1992). The 
aforementioned COMPARE program had been based on the insight that similar patterns 
of reactivity reflected similar mechanisms of reaction thus orienting researchers towards 
possible reaction mechanisms of the anti-tumour compounds screened. In other words, by 
recording a common end-point for a common dose of a single compound in 60 different 
cell lines, Weinstein’s group was able to develop ‘fingerprints’ for each of the 
compounds. Fingerprints could then be correlated with structural features of classes of 
compounds which, in turn, could be compared with the more than 460,000 compounds 
that had accumulated in the NCI database since the 1950s (Weinstein et al., 1997; 
Rindflesch et al., 2000). The NCI database was structured by a Drug Information System 
that contained coded information on the 3D structures of each compound in the bank and 
could thus be interrogated with regards to the relationship between ‘fingerprints’, and 
molecular structure (Milne et al., 1994). Weinstein and his collaborators combined the 
screen with other assays and used it to chart pathways of anti-oncogene activities 
(O’Connor et al., 1997; Rabow et al., 2002). As they put it:  
 
This approach to drug discovery and molecular pharmacology can be 
likened to a clinical trial with 60 patients (cell types) each profiled with 
respect to a variety of molecular markers and each treated with 60,000 
different agents, one at a time. It can also be considered as a hypothesis 
22 
generator based on a set of 60,000 X 60 = 3.6 million pharmacology 
experiments. (Weinstein et al., 1997, p. 348) 
 
Finally, by the time Brown and Weinstein met, Weinstein’s group had already set about 
analyzing the screening system at the protein level using gel electrophoresis (Myers et al., 
1997). Given the foregoing, it is not outlandish to suggest that microarrays were simply 
the next step. 
Microarrays, Profiles and Signatures 
Three months prior to the article on DNA microarrays, The Scientist had produced yet 
another article in its ‘Hot Papers’ series entitled “Researchers Profile Cancer Cells 
Through Gene Expression” (Kling, 2002a). This time, The Scientist inquired into the 
conditions surrounding the production of two articles that “had broken through the 
barriers and established relationships between gene expression profiling and the biology 
and clinical outcome of diffuse large B-cell lymphoma”. One of the two articles 
(Alizadeh et al., 2000), once again the outcome of a collaborative project between 
Stanford University and the NCI, was cited as “the first example of a clinically relevant 
classification of cancer using gene expression profiling” (Kling, 2002a). We will restrict 
ourselves to comments on this article, that provided a genetic profile of two different 
lymphoma populations.  
 
The authors claimed to have shown that what used to be treated, for lack of reliable 
means of discriminating between subgroups, as a single disease entity corresponded, 
when examined using microarray technology, to two molecularly distinct diseases. 
Molecular genetics is thus said to have succeeded in a domain where morphology 
“largely failed owing to diagnostic discrepancies arising from inter- and intra-observer 
irreproducibility” (Alizadeh et al., 2000, p. 503). The microarray used by the authors—
called Lymphochip—was designed to produce traces or readouts of both normal and 
pathological gene activation events within the framework of the development of the 
immune response. The two principal components of the Lymphochip—DNA derived 
from normal and pathological samples—shared the same space of representation.  
 
The visual demonstration of the article’s main claim consisted in the display of the color 
patterns produced by the differential expression of hundreds of genes sorted according to 
three colour-coded categories of intensity: high (red) medium (black) and low (green) 
(see Figure 7 for a simplified version of the original imagery). These distinctive colour 
patterns—the result of statistical manipulation of the raw data produced by the electronic 
microarray scanning equipment—were said to correspond to the characteristic profile of 
distinct pathological entities. Two things should be noted here. First, the starting 
material—the tissues samples from which the genetic material was extracted—had 
already been characterized as normal or pathological according to morphological and IPT 
criteria. The patterns, in other words, were categorized and explained by the 
morphological and immunophenotypic origin of the samples from which the genetic 
material was derived.  Second, and most importantly, the pathological events were 
ultimately translated into a qualitative pathological sign, a profile, rather than into a 
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quantitative description of the level of gene expression as measured by fluorescence 
intensities. 
 
FIGURE 7 
 
A microarray profile of lymphoma samples showing the existence of two distinct 
types of lymphoma. Original in colour. The colour-coded genes were selected and 
arranged using a clustering algorithm in order to produce a contrasting colour 
pattern. For this black and white version we have enhanced the grey scale (using 
darker greys for the red colour and lighter greys for green) in order to give an 
approximate idea of the plaid colour pattern (bottom left, top right: 
predominantly red; top left, bottom right: predominantly green). Reprinted 
from Staudt (2001, p. 38), © 2001, with permission from Elsevier Science. 
By electronically collating individual, profile-generating microarray experiments, 
researchers hope to reach an even higher aggregation level to generate what, in yet 
another leap of metaphorical imagination, they term signatures (Shaffer et al., 2001, p. 
384). The latter would provide information on “how cells differentiate, respond to 
stimuli, employ transcription factors, and react to drugs”. In turn, the development of a 
gene expression signatures database is seen as a possible solution to the problem of 
comparing gene expression data produced by different laboratories with different tools. 
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Instead of speculating on the future, we prefer to examine, in the next section, how 
microarrays have so far done in routine immunopathological applications. 
Microarrays in Clinical Routines 
Consider a recent (2003) advertisement (Figure 8) by Ardais, a company devoted to 
“connecting genomics and human disease”.16 The left side of the ‘A’ (A as in Ardais) 
displays the four letters (ATCG) of the genetic code and thus represents the biological 
(genomics) side of the equation. The right side of the ‘A’ shows a tissue sample under the 
microscope, signifying the morphological tradition in clinical pathology and thus human 
disease. The connecting line between these two elements, the one that completes the ‘A’, 
is a DNA microarray, that thus acts as the bridge between biology and medicine. 
FIGURE 8 
 
Advertisement (2003) by Ardais Corporation. See text for explanations. 
Reprinted with permission from Ardais Corporation (Lexington, MA).  
Ardais’s advertisement belongs to the register of promissory science, i.e., the strategy of 
depicting the future that, it is hoped, by shaping expectations will drive research in the 
                                                          
16 In 2002, the company launched the National Clinical Genomics Initiative in collaboration with several 
U.S. medical institutions. For additional information about this initiative and Ardais Corporation, see: 
http://www.ardais.com. 
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intended direction.17 From a performative point of view, such an activity is hardly empty 
speculation. In an innovative field of science, statements about the future enrol support 
and resources, enable interactions between actors, and guide the design of artefacts 
(Hedgecoe & Martin, forthcoming). Many of the statements we will discuss in this 
section participate in this mode of discourse. 
 
The routine use of microarray techniques within the clinic is predicated upon the solution 
of a number of issues that define the complex interaction between biological and clinical 
practices in the era of biomedicine. The first is the extent to which the technique can 
provide independent and novel information concerning diagnosis, classification and 
prognosis: independent and novel, that is, when compared to pre-existing clinical 
routines. This is well known in the field. Todd Golub, Eric Lander and their colleagues at 
the MIT Center for Genome Research were clearly aware of the need for microarrays to 
acquire independent status in order to obtain clinical success. Among the earliest and 
most highly cited entrants into the diagnostic field, they claimed to have invented a 
technique “that automatically discovered the distinction between acute myeloid leukemia 
and acute lymphoblastic leukemia without previous knowledge of these classes”. They 
further claimed that such a technique could be used as “a general strategy for discovering 
and predicting cancer classes for other types of cancer, independent of previous 
biological knowledge” (Golub et al., 1999, p. 531). In a subsequent special editorial for 
the New England Journal of Medicine entitled “Genome-Wide Views of Cancer”, Golub 
drew the obvious conclusion. Previous taxonomies would be displaced and clinical 
practice would have to adjust: 
 
The increasing understanding of molecular medicine will shift clinical 
practice from empirical treatment to therapy based on a molecular 
taxonomy of disease. Physicians will be prescribing rationally designed 
drugs that have increased efficacy and reduced toxicity. (Golub, 2001) 
 
Echoing Golub, an extensive review of microarray technology in the Journal of Clinical 
Pathology warned pathologists that if they did not embrace the technology, they ran the 
risk being squeezed out of the field. In particular:  
 
If pathologists neglect the potential of these processes at an early stage, it is 
not unthinkable that in the future their task will be limited to judging 
whether or not a sample contains material for microarray analysis or 
whether a tumor’s histology is compatible with the more precise diagnosis 
made by geneticists or chemists, or just handing over samples to specialists 
from other disciplines after dissection. Even worse, such samples may be 
taken from the specimen before they are sent to the pathology department. 
(Snijders et al., 2000 p. 293) 
 
Similarly, the Journal of Pathology told its readers:  
                                                          
1717 Several articles have recently discussed trend-promotion in science and technology. See Guice (1999) 
for a ground-breaking formulation that focuses, however, on information technology. In the medical field, 
this theme has been discussed both by practitioners (Baue, 2003) and  by social scientists (e.g., Hedgecoe & 
Martin, forthcoming). 
26 
 
As pathologists in the future, none of us will be able to avoid DNA 
microarrays and there may come a time when tumor RNA is routinely run 
on arrays to give an accurate read-out of the patient’s prognosis, and even a 
prescription for treatment! (Maughan, Lewis  & Smith, 2001, p. 6) 
 
Equally as enthusiastic, although stated in the conditional, a similar review in Nature 
Medicine opined:  
 
New technologies such as expression arrays, which allow us to monitor the 
expression of thousands of individual genes, could overcome the 
limitations of old methods of diagnosis and prognosis based on a limited 
number of markers. (He & Friend, 2001, p. 658). 
 
Although the previous quotes imply that pathologists are passive receptacles for the new 
technologies invented in the basic sciences, the practice of biomedicine entails 
considerably more interaction and a number of options and strategies are open to, and 
have been pursued by, pathologists and clinicians. To begin with, pathologists have 
appropriated the microarray technologies for their own purposes. Guido Sauter and his 
colleagues at the Institute of Pathology in Basel Switzerland, in collaboration with the 
NIH Human Genome Research Institute have invented a tissue microarray that inverts the 
principle of the DNA microarray: rather than following thousands of genes through a 
single tissue specimen, they have organized thousands of specimens on a single slide in 
order to follow a single gene product (Richter et al., 2000; Kononen et al., 1998). 
Commenting on this work in the Journal of Molecular Diagnostics, Lichter (2000, p. 
172) pointed out that:  
 
Although they stress the point that their study was accomplished within 2 
weeks, this number does not account for the previous efforts to carefully 
analyze archived material for the generation of the arrays. Nevertheless, the 
comprehensiveness of the study and the speed with which it was performed 
are more than impressive. These kinds of analyses will certainly change the 
world of publications in the field of pathology. 
 
Secondly, microarrays can also be aligned with work already underway. Researchers in 
Finland, for example, used microarray techniques to investigate patients that had first 
been classified according to traditional clinical, morphological, cytogenetic, 
immunophenotypic and staging techniques. They thus produced a staged cohort of a 
subclass of chronic leukaemia patients that had a specific chromosomal deletion and 
immunophenotype prior to microarray investigation. 
 
The microarray used by the Finnish team did not monitor thousands of genes as is so 
often the case. A Becton-Dickinson subsidiary, Clontech, had simplified and focused the 
process by producing ‘application-targeted arrays’ that selected genes that reflected the 
specific functions and disorders of the cells in question, as defined by previous 
investigations of and interventions upon the disease. Thus, using an ‘integrated platform’, 
namely the AtlasTM Human Hematology Array containing 440 genes (Anon., 1998), they 
isolated a cluster of up-regulated genes of known normal and pathological function 
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(Aalto et al., 2001). Notice that the genes were selected in order to create a biomedical 
device, one that would enable researchers to explore both the immune process and 
immune malignancies.  
 
Third, some commentators have suggested that the use of thousands of genes to 
differentiate within cancer classes constitutes overkill. The theory of oncogenes says that 
at best several hundred genes are mutated in most cancers. Richard Wooster (2000, p. 
328) of Britain’s Institute of Cancer Research thus suggests that as few as 10 to 20 genes 
could be used to differentiate between groups of tumours and consequently remarks that:  
 
We can marvel at the amount of data being produced by DNA expression 
arrays, but they could be considered as just a fishing exercise to identify a 
handful of genes that have a diagnostic potential. 
 
In this respect, molecular profiling can be seen as more of the same; just as IPT was 
articulated with histology, so too, will molecular profiling ultimately be forced to address 
its relation with morphology. As one of the keynote speakers at the Inaugural Association 
for Molecular Pathology Companion Meeting held at the United States and American 
Academy of Pathology Meeting suggested: 
 
In a sense, pathologists already use gene expression studies diagnostically 
on a daily basis in the form of immunohistochemistry. Expression profiling 
provides a supraexponential increase to the amount of gene expression data 
available on a given tumor, but lacks the topographical information of 
immunohistochemistry. (Ladanyi et al., 2001, p. 92) 
 
The plus ça change attitude, however, belied a more serious purpose to the address, 
namely a call to arms for pathologists. As the speaker went on to point out, unlike 
immunohistochemistry or even cytogenetics, “expression profiling may require less prior 
expert histopathological ‘triage’ than any prior ancillary technique” (Ladanyi et al., 2001, 
p. 92). Given these conditions, the following question no doubt seemed inevitable: “Will 
expression profiling evolve into another ‘ancillary’ technique or will it come to be seen as 
an alternative to expert surgical pathology?” This is certainly not the first time that such a 
question has been put to pathologists. Indeed, the frozen section technique raised similar 
fears at the turn of the last century (Wright, 1985) The corresponding answer is no doubt 
just as old:  
 
The extent of involvement of the pathology community in the further 
development of microarray-based expression profiling as a diagnostic test 
may determine the nature of its ultimate relationship to conventional tissue-
based diagnoses. (Ladanyi et al., 2001, p. 93) 
 
Here is one form of involvement. Spurred by the studies from Staudt’s laboratory, a 
French group of haematopathologists took up the challenge of producing a study “to aid 
in the transition of microarray technology into routine use”(Dales et al., 2001, p. 17). 
Rather than assuming that the microarray data were incommensurable with data obtained 
by older techniques, they sought correlations between microarrays and existing 
immunohistochemistry techniques. In particular, they used immunohistochemistry to 
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target intercellular proteins implicated in cell death and showed that the results so 
obtained correlated with those produced by (commercially available) microarrays. They 
thus concluded: “This suggests that, in the future, pathologists might be able to analyze 
by [immunohistochemistry] potential markers of interest previously identified by array 
technology” (Dales et al., 2001, p. 23). In other words, they turned the chronological 
relationship upside down by translating microarrays into a legitimating tool for pre-
existent immunopathological techniques. 
 
Closer to the clinical world, a review in JAMA enumerated a number of “possible pitfalls 
that may undermine the authority of the microarray platform” (King & Sinha, 2001, p. 
2280). The problems—sample selection, comparability, archiving and clinical and 
biological significance—all revolved around problems of regulation and the articulation 
of microarrays with existing platforms that determine gene function such as RT-PCR and 
knock-out mice. Notice, however, that while none of the ‘pitfalls’ are fatal, their solution 
is part of the process of the constitution of microarrays as a functioning biomedical 
platform and not an external problem. They are problems inherent to the management of 
microarrays (Lee et al., 2000; Becich, 2000). 
 
A recent review of the technique in Nature Genetics Reviews also warns clinical readers 
of a number of problems attendant upon the alignment of microarrays with existing 
routines and established practices in pathology, such as the routine fixing of tissues in 
formalin. To begin with, gene expression studies require intact RNA. RNA is degraded to 
an unknown extent during formalin fixation. Freezing the tissue of interest can help 
preserve the RNA; it inconveniently, however, compromises morphology. This is not 
necessarily the case in non-formalin based procedures such as those that use alcohol. 
Even here, however, further problems remain; one must, for example, process the 
material with considerable dispatch. And, as the same review points out: “investigators 
face an uphill battle in convincing surgeons and practicing pathologists to process the 
tissue obtained at surgery rapidly to preserve all the macromolecules of interest” (Liotta 
& Petricoin, 2000, p. 49). Pathological expertise and mobilization of the routines that 
underlie this skill is also required to isolate the initial pathological material. Biopsy 
specimens are in fact three-dimensional structures that contain a variety of cell 
populations. Explicit comparison between normal and pathological cells depends upon a 
prior visual inspection of the biopsy material in order to separate the two types. 
Nonetheless, some pathologists fear less losing time during biopsy to placate microarray 
enthusiasts, as implied in the previous quote, than losing the control over the resulting 
specimens and the downstream information. 
 
Promoters of the microarray platform for routine clinical use are aware that it is possible 
that the aforementioned work-arounds and the problems sketched above may in fact 
block entry of the microarray platform into routine clinical use. Addressing a clinical 
audience, Golub admitted that not only are microarrays “often viewed as screens to 
identify markers for traditional diagnostics, such as immunohistochemistry, for routine 
clinical use” but that “the feasibility of routine clinical use of microarrays ... has yet to be 
established” (Ramaswamy & Golub, 2002, p. 1941). On the pathologists’ side of the 
barricade, part of the consensus reached at a 2000 symposium held by the Royal College 
of Pathologists on the molecular genetics of solid tumours was that, “aside from the use 
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of gene rearrangement studies in haematological malignancies, genetic information has 
thus far offered little in the way of disease diagnosis and patient management” 
(Tomlinson & Ilyas, 2001, p. 202). The College went on to establish a committee to 
develop a framework for the introduction of molecular diagnosis into routine practice, for 
“there is a risk that technology will be used simply because it is available” (Tomlinson & 
Ilyas, 2001, p. 202). 
Conclusion 
Compared to the representations made by their promoters, what is often perceived as the 
introduction of molecular biology into the clinic has been at once both quicker and slower 
than expected. It has been quicker insofar as to speak of introduction is in itself 
misguided: clinical research is more closely entwined with basic biology than is often 
imagined. As we have repeatedly argued in this text, RFLPs, PCR, RT-PCR and 
microarrays were not so much transferred to the clinic as they were developed within the 
framework of biomedicine where clinical concerns and model diseases form the horizon. 
The widespread adoption of molecular genetic techniques for routine clinical testing, 
however, is slower than expected insofar as the use of techniques in clinical research does 
not imply their use in clinical practice.  
10 
 
To understand why this is so, we can redescribe these techniques within the larger context 
of a biomedical platform, as exemplified in this text. The work of articulation and 
regulation, or, in other words, the ongoing mutual adjustments between laboratory and 
clinical practices are constitutive aspects of a platform that enters routine clinical use. 
The mundane nature of this kind of work, essential though it is, often leads social  
scientists to overlook its role in biomedical innovation. Its importance, however, is not 
missed by actors in the field. A recent promissory survey of microarray technologies co-
authored by a group of FDA experts centred on the “development of a cooperative 
framework among regulators, product sponsors, and technology experts” as a sine qua 
non condition for turning the potential benefits of these technologies into clinical reality 
(Petricoin III et al., 2002, p. 474). Regulation, in this context, appears to be broadly 
understood, since it implies, among other things, the demonstration of “sufficient 
sensitivity, specificity, reproducibility, robustness, reliability, accuracy, precision and 
clinical relevance” of a given platform (Ibid., p. 476). The determination of clinical 
relevance, in itself, is a tall order, and one that links narrowly defined regulatory tasks to 
the development of new knowledge and innovative practices. We need, then, to invert the 
equation: what holds together and separates the various elements of a platform, is not 
how they are produced but how they are regulated. The production of novelty is the result 
of regulation for regulation ultimately defines significance. 
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